Hikma PharmaceuticalsHKMPY 87 EBITDA Margin % is 23.83% as of Dec. 2025, which is 0% above its 10-year median of 23.78. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.75 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 78.74% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hikma Pharmaceuticals EBITDA Margin % Related Terms
Hikma Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPY vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPY) has a EBITDA Margin % of 23.83% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hikma Pharmaceuticals and its competitors. This is near median its historical median of 23.78. Over the past decade, Hikma Pharmaceuticals' EBITDA Margin % has ranged from 19.20 to 30.12. According to the industry distribution chart, Hikma Pharmaceuticals ranks #203 out of 955 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Hikma Pharmaceuticals' EBITDA Margin % too high?
Hikma Pharmaceuticals' current EBITDA Margin % of 23.83% is near median its 10-year median of 23.78. Over the past 10 years, this metric has ranged from a low of 19.20 to a high of 30.12. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Hikma Pharmaceuticals' value of 23.83% is 91.6% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #203 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #203 out of 955 companies for EBITDA Margin %. This places Hikma Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Hikma Pharmaceuticals' value of 23.83% is 91.6% above this benchmark. Historically, Hikma Pharmaceuticals' own EBITDA Margin % has ranged from 19.20 to 30.12 over the past decade. While the company's 10-year median is 23.78 vs. the industry median of 12.44, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current EBITDA Margin % of 23.83% is 91.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current EBITDA Margin % is 23.83%, which is near median its own 10-year median of 23.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.75, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current EBITDA Margin % is 23.83%, which is near median its 10-year median of 23.78 and 91.6% above the Drug Manufacturers industry median of 12.44. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current EBITDA Margin % is 23.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.75.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPY:
EBITDA Margin %: 23.83% (near median its 10-year median of 23.78)
GF Value™: $56.75 vs. price of $41.23 (27.3% below fair value)
Industry Position: 91.6% above the Drug Manufacturers median (#203 of 955)
No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score
Get the complete analysis for HKMPY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPY has been successfully added to your 
